Recombinant alpha-interferon as salvage therapy in multiple myeloma
| Autor: | Jacobs, P, Le Roux, Ingrid M, Wood, L, King, HS |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Zdroj: | South African Medical Journal; Vol 76, No 8 (1989) |
| ISSN: | 2078-5135 0256-9574 |
| Popis: | Ten patients with end-stage multiple myeloma refractory to conventional chemotherapy and hemibody irradiation received recombinant α-interferon as salvage therapy. The median duration of treatment was 8 weeks. One patient had an objective response and survived 8 months, whereas in the remaining 9 patients the disease progressed and median survival was 11,5 weeks. Side-effects were substantial and included confusion with extreme weakness, resulting in 5 patients refusing further therapy. The low response rate and the morbidity in this pilot study resulted in its discontinuation and the conclusion that recombinant α-interferon as singleagent therapy used for salvage in patients with refractory myeloma is of no value.S Afr Med J 1989; 76: 100-102 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|